GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Indrayani Biotech Ltd
Indrayani Biotech Rights Issue: LOF and CAF Approved on 28-04-2026
FUNDRAISE ● No Immediate Change LOW RISK
📅 Filed on BSE: 28 Apr 2026, 05:13 PM IST  ·  BSE ID: 6ed53f68-8ed1-46eb-83ee-2033eaf3b84f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board committee approved the official offer documents and application forms needed to sell new shares to existing shareholders as part of a Rs. 49.90 crore fundraise.
🤖 AI Summary
  • Rights Issue Committee approved Letter of Offer and Abridged Letter of Offer on 28 April 2026
  • Composite Application Form format and renunciation process instructions finalised and approved
  • Follows 9 April 2026 approval of Rs. 49.90 crore partly paid rights issue expansion
  • Rights issue expands equity by 71% to 7,80,62,153 shares post-subscription
  • ISIN INE007C20013 confirmed for rights entitlements on 21 April 2026
🔢 Key Numbers — exact figures from BSE filing, not rounded
Rights Issue Size
Rs. 49.90 crore
Equity Expansion Post-Subscription
71%
Post-Subscription Share Count
7,80,62,153 shares
Rights Entitlement ISIN
INE007C20013
🏢 How This Affects the Company
💰
Financial Impact
Approval of LOF and CAF documentation clears the path for Rs. 49.90 crore capital inflow via partly paid equity expansion of 71% to 7,80,62,153 shares.
👥 What This Means For Shareholders
✅
Action Required
Eligible shareholders must await subscription opening notice. Check BSE announcements for subscription dates, application instructions, and payment schedules.
👤
Who Is Affected
All existing registered shareholders as on record date will receive rights entitlements proportional to existing shareholding. Non-subscribing shareholders face 71% equity dilution.
🔍
Management Signal
Committee execution discipline confirmed — documentation prepared on schedule following 9 April 2026 rights issue approval, signalling intent to close fundraise promptly.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Subscription opening date — confirm via BSE Regulation 30 disclosure within 2-3 days
Subscription closure date and allotment timeline — track for capital receipt and share issuance
Partly paid-up call schedule — monitor payment due dates to avoid forfeiture of partially paid shares
LOW RISK Documentation approval is routine procedural step. Risk emerges only if subscription falls short of target or shareholder uptake is weak.
💡 Investor Takeaway
Indrayani Biotech's Rights Issue Committee approved offer documents (LOF, ALOF, CAF) on 28 April 2026. Rs. 49.90 crore partly paid rights issue now operationalised with ISIN INE007C20013. Equity expands 71% to 7,80,62,153 shares post-subscription. Renunciation process instructions finalised.
⚖️ Strengths & Concerns

✅ Positives

  • Rights issue framework and documentation approved on schedule, supporting Rs. 49.90 crore capital raise plan
  • ISIN assigned (INE007C20013) and renunciation process documented, reducing operational risk in execution
📅 Company Track Record
Indrayani Biotech initiated rights issue framework on 6 April 2026 (RIC meeting scheduled). Committee approved issue parameters on 9 April 2026 (Rs. 49.90 crore, 71% equity expansion, 3,25,25,897 partly paid shares at Rs. 15 fully paid). ISIN INE007C20013 assigned 21 April 2026. LOF/CAF approvals follow on 28 April 2026.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.